BioMatrix Expands Ambulatory Care with Acquisition of LUX Infusion for Enhanced Patient Services
- BioMatrix Infusion Pharmacy acquires LUX Infusion to enhance access and quality in ambulatory infusion care.
- The acquisition integrates LUX Infusion's centers and skilled teams, improving patient outcomes nationwide.
- LUX Infusion's accreditation strengthens BioMatrix’s commitment to high-quality, value-based care in infusion therapy.
Strategic Expansion in Ambulatory Infusion Care: BioMatrix Acquires LUX Infusion
BioMatrix Infusion Pharmacy, headquartered in Plantation, Florida, takes a significant step forward in its mission to enhance access and quality in ambulatory infusion care through its recent acquisition of LUX Infusion. Effective October 17, 2025, this acquisition enables BioMatrix to integrate LUX Infusion's three advanced centers in Alaska into its national platform. With LUX Infusion's established reputation for clinical excellence and strong collaborations with providers and payers, this move positions BioMatrix to deliver improved patient outcomes and experiences across the United States.
The integration of LUX Infusion is a strategic enhancement for BioMatrix, as it not only adds physical locations but also bolsters clinical capabilities through LUX's highly skilled care teams. CEO Ted Kramm emphasizes that this partnership aligns with BioMatrix’s overarching goal of increasing innovation within ambulatory care. The acquisition also allows BioMatrix to extend its home infusion nursing services into the Pacific Northwest, offering patients a broader range of care options. With LUX Infusion's recent NICA accreditation and recognition as an AICE-Ambulatory Infusion Center of Excellence, BioMatrix further strengthens its commitment to high-quality, value-based care in the infusion therapy sector.
By bringing LUX Infusion into its fold, BioMatrix aims to solidify its standing as one of the premier infusion pharmacy providers in the nation. This acquisition is expected to significantly enhance patient access to infusion therapy, especially for those with complex and chronic conditions. As the healthcare landscape continues to evolve, the strategic benefits of this acquisition are poised to drive growth and foster deeper relationships with healthcare partners, ultimately leading to improved patient outcomes and satisfaction in the ever-important field of ambulatory infusion care.
In addition to enhancing its operational capacity, BioMatrix’s acquisition of LUX Infusion signifies an important trend in the healthcare industry, where companies increasingly seek to expand their service offerings through strategic partnerships and acquisitions. This move reflects a growing recognition of the value of integrated care models in addressing the complexities of patient needs.
The focus on quality and accessibility is further underscored by LUX Infusion's established care model, which can now be replicated across BioMatrix’s national network. This acquisition not only enhances BioMatrix’s service capabilities but also signals a commitment to advancing the standards of care within the infusion therapy sector.